Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases – Business Wire (press release)
|
Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases
Business Wire (press release) BOSTON & LONDON–(BUSINESS WIRE)–NightstaRx Limited (“Nightstar”), a late-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, today announced the completion of a $45 million Series C financing transaction. |
